



Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 071949-5301	SERIAL NO. 09/835,298
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION Submitted on July 10, 2002 (Use several sheets if necessary)		APPLICANT: Jeffrey R. Dahlen et al.	
		FILING DATE: 04/13/2001	GROUP ART UNIT: 1614 1641

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,580,722	12-03-1996	Foulkes et al.	435	6	
	A2	5,786,163	07-28-1998	Hall	435	7.92	
	A3	6,117,644	09-12-2000	DeBold	435	7.1	
	A4						
	A5						
	A6						
	A7						

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
<i>dl</i>	B1	WO 91/09627	07-11-1991	Hedner et al.				
	B2							
	B3							
	B4							


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	International Search Report in PCT Application No. PCT/US02/11441 dated July 2002						
	C2							
	C3							
	C4							
	C5							

EXAMINER 	DATE CONSIDERED 7/25/05
---	----------------------------

- * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

RECEIVED
 JUL 17 2002
 TECH CENTER 1600/2800



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 20, 2005

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	DAHLEN et al.
Group Art Unit	1641 1641
Examiner Name	Gabel
Attorney Docket Number	071949-5301

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
[Signature]	A1	5786163		Hall	07-28-1998	
	A2	6627457		Pandian et al.	09-30-2003	
	A3	6670138		Gonzalez-Zulueta et al.	12-30-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
[Signature]	A4	Huttunen et al., "Coregulation of neurite outgrowth and cell survival by amphotericin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. The Journal of Biological Chemistry, 275:40096-40105, 2000.	
	A5	Mussack et al., Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanism. Resuscitation, 49:193-199, 2001.	
	A6	Yakovlev et al., Activation of CPP32-Like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. The Journal of Neuroscience, 17(19): 7415-724, 1997.	
	A7	International Search Report for international application No. PCT/US04/26984	
[Signature]	A8	Notice of References Cited, PTO-892, Part of Paper No. 20041202 from U.S. Application No. 10/225,082 filed August 20, 2002.	

Examiner Signature


Date Considered

7/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet 1 of 7

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614 (64)
Examiner Name	
Attorney Docket Number	071949-5301

RECEIVED
DEC 28 2001
U.S. PATENT & TRADEMARK OFFICE
CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JCL	A1	5,480,792	US A	Buechler et al.	01-02-1996	
	A2	5,525,524	US A	Buechler et al.	06-11-1996	
	A3	5,631,171	US A	Sandstrom et al.	05-20-1997	
	A4	5,679,526	US A	Buechler et al.	10-21-1997	
	A5	5,795,725	US A	Buechler et al.	08-18-1998	
	A6	5,824,799	US A	Buechler et al.	10-20-1998	
	A7	5,851,776	US A	Valkirs	12-22-1998	
	A8	5,885,527	US A	Buechler	03-23-1999	
	A9	5,922,615	US A	Nowakowski et al.	07-13-1999	
	A10	5,939,272	US A	Buechler et al.	08-17-1999	
	A11	5,947,124	US A	Buechler et al.	09-07-1999	
	A12	5,955,377	US A	Maul et al.	09-21-1999	
	A13	5,985,579	US A	Buechler et al.	11-16-1999	
	A14	6,019,944	US A	Buechler	02-01-2000	
	A15	6,113,855	US A	Buechler	09-05-2000	
	A16	6,143,576	US A	Buechler	11-07-2000	
	A17	6,147,688	US A	Clair	11-14-2000	
	A18	6,156,521	US A	Buechler et al.	12-05-2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner
Signature

[Signature]


Date
Considered

7/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1240B-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: December 7, 2001 (use as many sheets as necessary)		Complete if Known	
		Application Number	09/835,298
		Filing Date	04/13/2001
		First Named Inventor	Jeffrey R. Dahlen et al.
		Group Art Unit	1614
		Examiner Name	
		Attorney Docket Number	071949-5301
Sheet	2	of	7

RECEIVED
DEC 28 2001
PATENT CENTER 1600/2900


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
Cef	A19	ALEXANDER et al., "30-Day and 6-Month Mortality in Proportional to Magnitudr of Peak Creatine Kinase Elevation in the Non-ST-elevation Acute Coronary Syndromes," Circulation (Supp.), 1998, p. I-629.	
	A20	ANTMAN et al., "Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality In Patients with Acute Coronary Syndromes," The New England Journal of Medicine, 1996, p. 1342-49, Vol. 335, No. 18.	
	A21	ANTMAN et al., "Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction," Circulation, 1999, p. 1593-1601, Vol. 100.	
	A22	ARAKAWA et al., "Relationship Between Plasma Level of Brain Natriuretic Peptide and Myocardial Infarct Size," Cardiology, 1994, p. 334-340, Vol. 85.	
	A23	ARAKAWA et al., "Plasma Brain Natriuretic Peptide Concentrations Predict Survival After Acute Myocardial Infraction," JACC, June 1996, p. 1656-61, Vol. 27, No. 7.	
	A24	BERGER et al., "B-Type Natriuretic Peptides (BNP and PRO-BNP) Predict Longterm Survival in Patients with Advanced Heart Failure Treated with Atenolol," Journal of the Heart and Lung Transplantation, 2001, p. 251, Vol. 20, No. 2.	
	A25	BRAUNWALD et al., "Unstable Angina: Diagnosis and Management," Clinical Practice Guideline No. 10 (amended), AHCPR Publication No. 94-0602, Rockville, MD: Department of Health and Human Services, 1994.	
	A26	CANNON et al., "Invasive Versus Conservative Strategies in Unstable Angina and Non-Q-Wave Myocardial Infarction Following Treatment with Tirofiban: Rationale and Study Design of the International TACTICS-TIMI 18 Trial," Am. J. Cardiology, 1998, p. 731-736, Vol. 82.	
	A27	CANNON et al., "Oral Glycoprotein IIB/IIIa Inhibition with Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) Trial," Circulation, 2000, p. 149-156, Vol. 102.	
A	A28	CHENG et al, "A Rapid Bedside Test for B-Type Peptide Predicts Treatment Outcomes in Payients Admitted for Decompensated Heart Failure: A pilot Study," Journal of the American College of Cardiology, 2001, p. 386-391, Vol. 37, No. 2.	
	A29	DAO et al., "Utility of B-Type Natriuretic Peptide in the Diagnosis of Congestive Heart Failure in an Urgent-Care Setting," Journal of the American College of Cardiology, 2001, p. 379-385, Vol. 37, No. 2.	

Examiner Signature		Date Considered	7/25/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet 3 of 7

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	071949-5301

RECEIVED
DEC 28 2001
PATENT CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
de	A30	DARBAR et al., "Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients with Acute Myocardial Infarction," Am. J. Cardiology, 1996, p. 284-287, Vol. 78.	
	A31	FISCHER et al., "Evaluation of a New, Rapid Bedside Test for...", Clinical Chemistry, 2001, p. 591-594, Vol. 47, No. 3.	
	A32	GRAYBURN et al., "Perflenapent Emulsion (EchoGen®): A New Long-Acting Phase-Shift Agent for Contrast Echocardiology," Clinical Cardiology, 1997, p. 1-12 – 1-18, Vol. 20 (Supp I).	
	A33	HAMA et al., "Rapid Ventricular Induction of Brain Natriuretic Peptide Gene Expression in Experimental Acute Myocardial Infarction," Circulation, 1995, p. 1558-1564, Vol. 92.	
	A34	HAMM et al., "Benefit of Abciximab in Patients with refractory Unstable Angina in Relation to serum Troponin T Levels," New England Journal of Medicine, 1999, p. 1623-1629, Vol. 340, No. 21.	
	A35	HORIO et al., "Serial Changes in Atrial and Brain Natriuretic Peptides in Patients with Acute Myocardial Infarction Treated with early Coronary Angioplasty," American Heart Journal, 1993, p. 293-299, Vol. 126.	
	A36	HUNT et al., "The Amino-Terminal Portion of Pro-Brain Natriuretic Peptide (Pro-BNP) Circulates in Human Plasma," Biochemical and Biophysical Research Communications, 1995, p. 1175-1183, Vol. 214, No. 3.	
	A37	KIKUTA et al., "Increased Plasma Levels of B-Type Natriuretic Peptide in Patients with Unstable Angina," American Heart Journal, 1996, p. 101-107, Vol. 132, No. 1.	


Examiner
SignatureDate
Considered

7/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet 4 of 7

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	071949-5301

RECEIVED
DEC 28 2001
TECH CENTER 1600/2001

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A38	KLOOTWIJK et al., "Acute Coronary Syndromes: Diagnosis," The Lancet, June 1999, p. 1109-1113, Vol. 132.	
	A39	KYRIAKIDES et al., "Brain Natriuretic Peptide Increases Acutely and Much More Prominently than Atrial Natriuretic Peptide during Coronary Angioplasty," Clinical Cardiology, 2000, p. 285-288, Vol. 23.	
	A40	LLOYD-JONES et al., "Electrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients with Unstable Angina Pectoris," Am. J. Cardiology, 1998, p. 1182-1186, Vol. 81.	
	A41	MARUMOTO et al., "Increased Secretion of Atrial and Brain Natriuretic Peptides During Acute Myocardial Ischaemia Induced by Dynamic Exercise in Patients with Angina Pectoris," Clinical Science, 1995, p. 551-556, Vol. 88.	
	A42	MORROW et al., "C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy," JACC, June 1998, p. 1460-5, Vol. 31, No. 7.	
	A43	MORROW ET AL., "Cardiac Troponin I for Stratification of early Outcomes and the efficacy of Enoxaparin in Unstable Angina: A TIMI-11B Substudy," JACC, 2000, p. 1812-1817, Vol. 36, No. 6.	
	A44	MOTWANI et al., "Plasma Brain Natriuretic Peptide as an Indicator for Angiotensin-converting-enzyme Inhibition After Myocardial Infraction," The Lancet, 1993, p. 1109-13, Vol. 341.	
	A45	NAGAYA et al., "Plasma Brain Natriuretic Peptide is a Biochemical Marker for the Prediction of Progressive Ventricular Remodeling after Acute Myocardial Infarction," American heart Journal, 1998, p. 21-8, Vol. 135.	

Examiner
Signature


Date
Considered

7/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet 5 of 7

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	071949-5301

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A46	NYMAN et al., "Very Early Risk Stratification by Electrocardiogram at Rest in Men with Suspected Unstable Coronary Heart Disease," Journal of Internal Medicine, 1993, p. 293-301, Vol. 234.	
	A47	OMLAND et al., "Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction," Circulation, 1996, p. 1063-1969, Vol. 93.	
	A48	OMLAND et al, "Plasma Cardiac Natriuretic Peptide Determination as a Screening Test for the Detection of Patients with Mild Left Ventricular Impairment," Heart, 1996, p. 232-237, Vol. 76.	
	A49	PATEL et al., "Early Continuous ST Segment Monitoring in Unstable Angina: Prognostic Value Additional to the Clinical Characteristics and the Admission Electrocardiogram," Heart, 1996, p. 222-228, Vol. 75.	
	A50	PATEL et al., "The Importance of Early Risk Stratification Using Continuous ST Segment Monitoring," European Heart Journal, 1998, p. 240-249, Vol. 19.	
	A51	RICHARDS et al., "Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin," Circulation, 1998, p. 1921-1929, Vol. 97.	
	A52	RICHARDS et al., "Neuroendocrine Prediction of Left Ventricular Function and Heart Failure After Acute Myocardial Infarction," Heart, 1999, p. 114-120, Vol. 81.	
	A53	RIDKER et al., "Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels," Circulation, 1998, p. 839-844, Vol. 98.	

Examiner
SignatureDate
Considered

7/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 7, 2001

(use as many sheets as necessary)

6

of

7

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	071949-5301

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
oe	A54	SAVONITTO et al., "Prognostic Value of the Admission Electrocardiogram in Acute Coronary Syndromes," JAMA, 1999, p. 707-713, Vol. 281.	
	A55	STEIN et al., "Natriuretic Peptides: Physiology, Therapeutic Potential, and Risk Stratification in Ischemic Heart Disease," American heart Journal, 1998, p. 914-923, Vol. 135.	
	A56	TALWAR et al., "Profile of Plasma N-terminal proBNP Following Acute Myocardial Infarction," European Heart Journal, 2000, p. 1514-1521, Vol. 21.	
	A57	TALWAR et al., "Plasma N-terminal Pro-Brain Natriuretic Peptide and Cardiotrophin 1 are raised in Unstable Angina," Heart, 2000, p. 421-424, Vol. 84.	
	A58	TATEISHI et al., "Transient Increase in Plasma Brain (B-Type) Natriuretic Peptide After Percutaneous Transluminal Coronary Angioplasty," Clinical Cardiology, 2000, p. 776-780, Vol. 23.	
	A59	TATEYAMA et al., "Concentrations and Molecular Forms of Human Brain Natriuretic Peptide in Plasma," Biochemical and Biophysical Research Communications, 1992, p. 760-767, Vol. 185, No. 2.	
	A60	THEROUX et al., "Acute Coronary Syndromes," Circulation, 1998, p. 1195-1206, Vol. 97.	
4	A61	TROUGHTON et al., "Treatment of Heart Failure Guided by Plasma Aminoterminal Brain Natriuretic Peptide (N-BNP) Concentrations," The Lancet, 2000, p. 1126-1130, Vol. 355.	

Examiner
Signature




Date
Considered

7/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1485PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet 7 of 7

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	071949-5301

RECEIVED
DEC 28 2001
COMM CENTER 1600/2900**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
ae	A62	VAN VELDHUISEN et al., "High Versus Low Dose ACE Inhibition in Chronic Heart Failure," JACC, 1998, p. 1811-1818, Vol. 32, No. 7.	
	A63	WEISE et al., "Gene Expression of Brain Natriuretic Peptide in Isolated Atrial and Ventricular Human Myocardium," Circulation, 2000, p. 3074-3079, Vol. 102.	
	A64	YASUE et al., "Localization and Mechanism of Secretion of B-Type Natriuretic Peptide in Comparison with Those of A-Type Natriuretic Peptide in Normal Subjects and Patients with Heart failure," Circulation, 1998, p. 195-203, Vol. 90.	
	A65	YOSHIMURA et al., "Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients with Congestive Heart Failure," Circulation, 1993, p. 464-469, Vol. 87.	
	A66	YUSUF et al., "Variations Between Countries in Invasive Cardiac Procedures and Outcomes in Patients with Suspected Unstable Angina or Myocardial Infarction without Initial ST Elevation," The Lancet, 1998, p. 507-514, Vol. 352.	

Examiner
SignatureDate
Considered

7/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.